Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis

Br J Dis Chest. 1987 Oct;81(4):341-8. doi: 10.1016/0007-0971(87)90182-3.

Abstract

Five hundred and twenty-six patients suffering from chronic bronchitis were randomized to receive either N-acetylcysteine (NAC) or placebo during a 6-month period. The aim was to compare the number of acute exacerbations in the two groups. General practitioners were asked to enter patients with a diagnosis of chronic bronchitis, based on the MRC criteria. We failed to find any statistically significant difference in the number of exacerbations between the two treatment groups although there was a slight trend towards improvement in the NAC group during the first 3 months of the trial. The tolerability was similar for both treatments. Patients taking NAC showed a reduction in number of days on which they were incapacitated and this result was statistically significant.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Acetylcysteine / therapeutic use*
  • Adult
  • Aged
  • Aged, 80 and over
  • Bronchitis / drug therapy*
  • Chronic Disease
  • Clinical Trials as Topic
  • Double-Blind Method
  • Female
  • Humans
  • Male
  • Middle Aged
  • Patient Compliance
  • Random Allocation

Substances

  • Acetylcysteine